Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
-
The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
-
Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19 by adopting patient-centric technologies to keep patients safe and studies on track. The article is published in PharmaFile Spring 2020 on page 40.
-
Improving access and reimbursement for specialty therapies
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, payers are scrutinising the economic value more closely. ICON experts discuss how clinical development can better satisfy the evidence needs of HTA bodies and payers.
-
ICON nabs former Optum, FDA and AstraZeneca exec as new chief medical officer
Fierce Biotech reports on ICON's appointment of Dr. Kristen Buck as its new chief medical officer.
-
The U.S. biosimilars market: Shaking the “laggard” label
An article by Katya Svoboda and Bob Swann which explores the fundamental differences in the regulatory processes and the market dynamics of the US and the EU which account for much of the discrepancy in the uptake of biosimilars.
-
Transforming cell and gene therapy trial design and execution
With over 400 dedicated Cell and Gene Therapy professionals globally, ICON has developed tools and best practices to transform CGT trial design and execution.
-
Translation services and the race for a coronavirus vaccine
An article featuring commentary from Adelina Lear regarding the role of language services in the drug development lifecycle.
-
Role of data in revolutionising the CRO industry
In a wide-ranging interview with PharmaBoardroom, ICON CIO, Tom O’Leary highlights the role of data in revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes.
-
The Significant Role of a Robust Regulatory Intelligence Process in Global Safety Submissions
Pharmacovigilance insights on the efforts towards the international standardisation of electronic transmission of drug safety information to achieve a unified objective of patient safety, written by Arinder Sihota and Trupti Gurjar, which featured in the March 2020 edition of Pharma Focus.
